Compare BILI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BILI | PRAX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | China | United States |
| Employees | 8088 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 9.6B |
| IPO Year | N/A | 2020 |
| Metric | BILI | PRAX |
|---|---|---|
| Price | $22.09 | $328.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $31.13 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 1.9M | 345.4K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.77 | N/A |
| Revenue Next Year | $9.59 | $7,758.26 |
| P/E Ratio | $122.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.16 | $34.89 |
| 52 Week High | $36.40 | $354.87 |
| Indicator | BILI | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 34.98 | 53.49 |
| Support Level | $21.84 | $282.49 |
| Resistance Level | $25.65 | $353.83 |
| Average True Range (ATR) | 0.63 | 16.69 |
| MACD | 0.01 | 1.67 |
| Stochastic Oscillator | 6.44 | 55.97 |
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing service. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, or ACG, catering primarily to Generation Z users. Over time, the platform has expanded its content ecosystem to cover a broader range of interests, successfully attracting a more diverse audience beyond its original Gen Z base.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.